{"entity":{"id":"nct06214143","kind":"trial","name":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of T3011 high dose in advanced solid tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.","summary":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06214143 by Shanghai Pharmaceuticals Holding Co., Ltd, with 68 participants planned, started 2024-01-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: T3011 high dose, T3011 middle dose and T3011 low dose.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06214143","url":"https://clinicaltrials.gov/study/NCT06214143"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["genfleet"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06214143","phase":"1/2","setting":"A Single-arm, Multi-center Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety, and Initial Efficacy of T3011 Herpesvirus Injection Combined With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","enrolled":68,"outcomes":[]},"route":"/trials/nct06214143/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/"}]}}